« Back
Home /
Cetrelimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)

Cetrelimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)

Item no.	DCC-A421-1mg
Manufacturer	DCChemicals
CASRN	2050478-92-5
Amount	1 mg
Quantity options	100 mg 10 mg 1 mg 5 mg
Specific against	other
Available
Manufacturer - Applications	Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 1 mg

available

Delivery expected until 12/11/2025

Compare

Add to wishlist

Get an offer

Request delivery time